ClinicalTrials.gg
RecruitingNCT04851678LISA-TSUpdated May 5, 2026

Longitudinal Impact of Stressors in Adults With Tourette Syndrome

An observational study in Tourette Syndrome, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Vanderbilt University Medical Center · Observational

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Planned enrollment
12th of 33
140 · median 90
Started
2021
with 7 others
Observational
33 of 139
6 open now
Primary completion
2027-03
later than 10 of 23 live
Registered
111th of 139
by date
Lead sponsor
6 of 139
Vanderbilt University Medical Center

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 12th largest by planned enrollment of the 33 observational ones that give a count, is one of 8 that started in 2021, is one of 33 observational ones, reaches primary completion later than 10 of the 23 other live ones, and was the 111th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

The Investigators propose a two-year, longitudinal pilot study of TS adults (>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and health-related quality of life (HRQOL).

Read the detailed description

Tourette syndrome (TS) is a widely prevalent neurodevelopmental disorder with limited treatment options,(1,2) substantial impact on quality of life in children(3-7) and adults,(4,8-10) and two-fold increased risk of premature death.(11,12) Tics are the defining feature of TS, and as a result, TS is often narrowly perceived in terms of tics alone. Tics themselves tend to wane in late adolescence, with distressing tics persisting in only one-third of TS patients.(13) Because tics generally diminish with age, the plight of adults with TS is often neglected. Over half of TS adults suffer from anxiety and depression,(10,14) and a similar percentage experience symptoms of attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), findings recently corroborated in our own clinical population.(10) Many TS adults struggle to form meaningful relationships with peers, and one-third feel inadequately supported by their families.(13) The burden of TS in adulthood extends beyond mental and social health. In a national registry cohort study, individuals with TS had a mortality rate ratio of 1.8 relative to healthy controls, even after controlling for comorbid psychiatric diagnoses.(11) The causes of more frequent premature death in TS populations are unclear, with many mechanisms implicated, including suicide,(15) traumatic accidents,(12) substance abuse,(16) metabolic disorders,(12,17) and complications from pharmacotherapy.(18,19)

Environmental stressors are also postulated to impact the course of TS.(20) An environmental stressor is any external condition or event that poses a threat to an individual's well-being.(21) Such stressors are known to alter brain development(22-24) and increase risk of adulthood psychopathology.(25,26) A single study has explored the role of environmental stressors in TS, finding that selected stressors predicted two-year tic and psychiatric symptom severity in a pediatric cohort (n=37 patients).(27) No similar investigations have been undertaken in TS adults. The Investigators hypothesize that environmental stressors are risk factors for more severe adult TS phenotype. The Investigators propose a two-year, longitudinal pilot study of TS adults (>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and health-related quality of life (HRQOL).

Aim 1. Determine influence of lifetime environmental stressors on tic severity in TS adults. Hypothesis: Number of lifetime stressors at baseline assessment is associated with greater tic severity at two year follow-up. Seventy adults with TS will be recruited from the Vanderbilt TS Clinic to complete a baseline assessment, consisting of validated clinical rating scales for tic severity (Yale Global Tic Severity Scale), common psychiatric comorbidities, and lifetime environmental stressors (Stress and Adversity Inventory for Adults, STRAIN). Because acute and chronic stressors exert differential physiologic and clinical-level effects,(28-31) the STRAIN assesses these separately. The Investigators will use multivariable linear regression to examine the influence of acute and chronic lifetime stressor count at baseline on tic severity at two years, controlling for baseline tic severity and psychiatric comorbidities, as well as anti-tic medications at follow-up. Results will clarify the impact of environmental stressors on tic severity in TS adults.

Aim 2. Determine influence of lifetime environmental stressors on depression in TS adults.

Hypothesis: Number of lifetime stressors at baseline assessment is associated with more depressive symptoms at two-year follow-up. Depression is the psychiatric symptom that most impacts adult functioning and QOL.(10) As part of baseline and follow-up assessments, Aim 1 participants will complete standardized, semi-structured psychiatric interviews (Mini International Neuropsychiatric Interview, MINI) and validated self-report depression scales (NeuroQOL-Depression). The statistical approach from Aim 1 will be adopted to examine the influence of acute and chronic lifetime stressor count at baseline on depression symptom severity at two years, again controlling for select confounds. Findings will delineate the effects of acute and chronic environmental stressors on depression in adults with TS.

Aim 3. Determine influence of positive childhood experiences on health-related quality of life (HRQOL) in TS adults. Hypothesis: Greater number of positive childhood experiences is associated with better HRQOL in TS adults at two-year follow-up. Positive childhood experiences partially mitigate the negative effects of adverse childhood experiences.(32) At baseline and follow-up visits, Aim 1 participants will report number and type of positive childhood experiences. They will also complete a validated HRQOL measure specific to TS: the Gilles de la Tourette-Quality of Life Scale (GTS-QOL). The Investigators will use multivariable regression modeling to examine the influence of positive childhood experiences on future HRQOL, controlling for environmental stressors and baseline HRQOL. Results will elucidate the potentially moderating role of positive childhood experiences on HRQOL in TS adults.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

Keywords

  • Stress
  • Environmental stress
  • Psychosocial stress
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adults (>18 years of age) with Tourette syndrome or other chronic tic disorder

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults (>18) meeting Diagnostic and Statistics Manual, 5th edition () criteria for Tourette syndrome, chronic motor tic disorder, or chronic vocal tic disorder
  • ability to provide
  • English proficiency

Exclusion criteria

Exclusion Criteria:

- significant medical, neurologic, or psychiatric diagnoses (e.g. uncontrolled epilepsy, chronic heart failure, schizophrenia) besides TS and its commonly co-occurring psychiatric diagnoses

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (estimated)
Patient registry
No

Groups and cohorts

  • Individuals with Tourette syndrome (TS)

    Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.

    Other: None - observational study

Interventions

  • OtherNone - observational study

    None - observational study

06

What researchers measure

Primary outcomes

  1. Total Tic Score from Yale Global Tic Severity Scale (YGTSS)

    Semi-structured, clinician-administered interview to assess tic severity. Total tic scores are a composite of motor tic scores (0-25) and phonic tic scores (0-25) based on 5 dimensions of tic severity: number, frequency, intensity, complexity, and interference. Total tic scores range from 0-50. Higher scores indicate great tic severity. The YGTSS is the gold-standard clinical rating scale for tic severity.

    Time frame: 2 years post-baseline assessment

  2. NeuroQOL-Depression Score

    NeuroQOL-Depression is a validated, 8-item self-report scale assessing symptoms of depression. Raw total scores range from 8-40; raw scores are converted to T-scores based on normative samples. Higher scores indicate more depressive symptoms. NeuroQOL-Depression is part of the Neuro-QOL (Quality of Life in Neurological Disorders) measurement system. The scale is designed to be completed with one minute.

    Time frame: 2 years post-baseline assessment

  3. Gilles de la Tourette Quality of Life Scale (GTS-QOL) Score

    The GTS-QOL is a 27-item self-report scale. Respondents rate each item on a Likert scale ranging from 0 ("no problem") to 4 ("extreme problem"). The scale is composed of four sub-scales: Psychological (11 items), Physical/Activities of Daily Living (Physical/ADL) (7 items), Obsessive-Compulsive (OC) (5 items), and Cognitive (4 items) (39). Item scores within each subscale are summed and then normalized to 100 to generate the subscale score. The four subscale scores are then summed and normalized to 100 to yield the total score. Higher scores indicate worse health-related quality of life.

    Time frame: 2 years post-baseline assessment

Secondary outcomes

  1. NeuroQOL-Anxiety Score

    NeuroQOL-Depression is a validated, 8-item self-report scale assessing symptoms of anxiety. Raw total scores range from 8-40; raw scores are converted to T-scores based on normative samples. Higher scores indicate more anxiety symptoms. NeuroQOL-Anxiety is part of the Neuro-QOL (Quality of Life in Neurological Disorders) measurement system. The scale is designed to be completed with one minute.

    Time frame: 2 years post-baseline assessment

  2. Adult ADHD Self-Report Screening Scale for DSM-V (ASRS-V) Score

    ASRS-V is a 6-question scale screening for symptoms of inattention and hyperactivity. Each item is rated 0 ("never") to 4 ("very often"). Total score is the sum of individual item scores. Higher score indicates more ADHD symptoms. In clinical populations, ASRS-V total score cutoff ≥ 14 is 81% sensitive and 70% specific for detecting ADHD.

    Time frame: 2 years post-baseline assessment

  3. Dimensional Obsessive-Compulsive Scale (DOCS) Score

    DOCS is a 20-item, validated self-report scale assessing for severity of obsessive-compulsive symptoms. Total score ranges from 0-80, with higher scores indicating more OCD symptoms. In clinical populations, DOCS total score cutoff ≥ 21 is 70% sensitive and 70% specific in distinguishing OCD from other anxiety disorders.

    Time frame: 2 years post-baseline assessment

  4. Mini International Neuropsychiatric Interview (MINI)

    The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a brief structured diagnostic interview for common DSM-V psychiatric disorders. Scale administration is typically 15-20 minutes. Scale output is presence/absence of psychiatric diagnoses currently and/or in the past.

    Time frame: 2 years post-baseline assessment

  5. Lifetime Adult STRAIN

    The STRAIN (https://www.uclastresslab.org/projects/strain-stress-and-adversity-inventory/) is a NIMH/RDoC-recommended online stress assessment system that measures individuals' lifetime exposure to different types of acute and chronic stress that have implications for health. STRAIN questions automatically adapt based on a user's responses. The STRAIN generates multiple stressor scores, including total stressor count and severity, childhood and adulthood stressor counts and severities, and domain-specific stressor counts and severities.

    Time frame: 2 years post-baseline assessment

  6. Multifactoral Assessment of Perceived Social Support (MAPSS)

    The MAPSS is an 8-item, unidimensional, validated, clinically relevant, self-report measure of social support.

    Time frame: 2 years post-baseline assessment

  7. Sensory Gating Inventory (SGI)

    The SGI is a 36-item, validated instrument assessing hyper- or hypo-sensitivity to sensory stimuli (primarily sight and sound). Each scale item is a statement to which participants must rate their agreement on a 6-point Likert scale (1 = "never true"; 6 = "always true"). The minimum score on the scale is 36; the maximum score is 216. Higher scores indicate more abnormal sensory experiences.

    Time frame: 2 years post-baseline assessment

  8. Body Perception Questionnaire-Short Form (BPQ-SF)

    The BPQ-SF is a self-report questionnaire that assesses the frequency of specific body stress reactions in organs that are innervated by the autonomic nervous system. Combined scores from organs throughout the body provide a measure of autonomic stress response patterns. The questionnaire has been used in a range of international neural, behavioral, and clinical studies and translated into several languages.

    Time frame: 2 years post-baseline assessment

  9. Emotion Regulation Questionnaire

    The Emotion Regulation Questionnaire is a 10-item, self-report questionnaire designed to assess individual differences in the habitual use of two emotion regulation strategies: cognitive reappraisal and expressive suppression. Participants rate each statement about emotion regulation on a 7-point Likert scale (1 = "strongly disagree"; 7 = "strongly agree").

    Time frame: 2 years post-baseline assessment

  10. Response to Stress Questionnaire-Interpersonal Stress (RSQ)

    The RSQ measures coping and involuntary stress responses. It begins with a checklist of stressors that pertain to interpersonal stress, which the participant rates in terms of how often each stressor has occurred in the recent past. The questionnaire then asks the participant to keep those specific stressors in mind when responding to the items that comprise the stress responses. Participants rate how often they use each coping method or experience each type of involuntary stress response on a scale of 1 (Not at all) to 4 (A lot). Some items require participants to select an answer on the 1 to 4 scale and write in additional information to describe specifically how they employed that particular coping strategy. The RSQ contains items to measure three types of coping and two types of involuntary stress responses. The measure thus yields five factors: primary control coping, secondary control coping, disengagement coping, involuntary engagement, and involuntary disengagement.

    Time frame: 2 years post-baseline assessment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Mar 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
Apr 20, 2021
StartActual
Sep 30, 2021
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 30, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04851678
Responsible party
David Isaacs (Assistant Professor, Neuro-Movement Disorders Division, Vanderbilt University Medical Center) — Principal investigator
First posted
Apr 20, 2021
Start date
Sep 30, 2021
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 5, 2026

Study contacts

Michelle Eckland, BS
Contact
michelle.r.eckland.1@vumc.org
615-875-7394
David A Isaacs, MD, MPH
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion